AstraZeneca diabetes drug cuts heart risks in major study

AstraZeneca's diabetes drug dapagliflozin (Farxiga) met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients. The cardiovascular (CV) profile of medicines to treat diabetes is an important focus for doctors and patients.

AstraZeneca's diabetes drug dapagliflozin (Farxiga) met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients. The cardiovascular (CV) profile of medicines to treat diabetes is an important focus for doctors and patients. In the 17,000-patient trial known as Declare, patients on dapagliflozin achieved a statistically significant and clinically important reduction in hospitalization for heart failure or CV death compared with those on placebo. Ludovic Helfgott, AstraZeneca's head of CV and metabolic diseases, believes the overall data suggests Farxiga could win expanded approval as a diabetes drug with proven heart benefits in a wide range of patients. "We have demonstrated with Declare that we have a cardiovascular outcome in a broad population and we believe that is something that needs to be recognized by regulators and the clinical community," says Helfgott. The study aimed to demonstrate dapagliflozin's value in patients without established CV disease, opening up a larger market that also covers so-called primary prevention. Industry analysts estimate the primary prevention population is about three times larger than that for secondary prevention. Full results from the Declare study will be presented on November 10 at the annual meeting of the American Heart Association.